Toxikon Launches New Website and Educational Resources
Leading preclinical CRO magnifies commitment to serving the life science industry
"For more than 40 years, Toxikon has shown that quality science and ongoing education are key to quickly and successfully developing medical products," said Dr. Laxman S. Desai, Chief Executive Officer and President. "We remain committed to helping our partners and clients bring novel therapies to market efficiently, and will stand by them through every step of the regulatory pathway. Our relaunched website is an important resource for prospective clients to understand the preclinical process and understand how to navigate that process efficiently."
Toxikon's new website features in-depth descriptions of preclinical tests and sample requirements;
"Toxikon's distinguished scientific staff not only fully understand medical device and pharmaceutical testing requirements;
For more information, please visit www.toxikon.com.
About Toxikon Corporation
Toxikon is a leading ISO 17025-accredited global preclinical contract research organization (CRO) providing in vivo, in vitro, and analytical testing services for the pharmaceutical, biotechnology, and medical device industries – helping those companies gain approval for their products quickly and bring them to market successfully. With over 40 years of broad and deep experience in navigating the dynamic regulatory landscape, Toxikon offers the expertise and technical skill necessary to supply the life science industry with the results needed to gain approval for innovative therapies and products, demonstrating safety and efficacy.
Page Updated Last on: Oct 26, 2018